NCT04629872 is a Phase 2 clinical trial of Fingolimod in Stroke Inflammation, sponsored by Ning Wang, MD., PhD..

Who is sponsoring NCT04629872?

NCT04629872 is sponsored by Ning Wang, MD., PhD..

What drugs are being tested in NCT04629872?

Interventions in NCT04629872: Fingolimod.

What condition does NCT04629872 study?

NCT04629872 studies Stroke Inflammation.

Is NCT04629872 still recruiting?

NCT04629872 is currently status unknown. Last updated 13 April 2022.

Last reviewed 2022-04-13 · How we verify

NCT04629872

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fingolimod in Endovascular Treatment of Ischemic Stroke

Status unknown Phase 2 Last updated 13 April 2022

What this trial tests

Phase 2 trial testing Fingolimod in Stroke Inflammation in 30 participants. Status unknown.

Timeline

12 November 2020

Primary endpoint
30 December 2022

30 December 2023

Quick facts

Lead sponsor	Ning Wang, MD., PhD.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	12 November 2020
Primary completion	30 December 2022
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

Fingolimod (FINGOLIMOD) — full drug profile →

Conditions studied

Stroke Inflammation — all drugs for Stroke Inflammation →

Sponsor

Ning Wang, MD., PhD.

Who can join

Adults 18 to 80, any sex, with Stroke Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This study aim to determine whether fingolimod enhance the action of endovascular treatment for acute ischemic stroke

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions.
Qin C, Yang S, Chu YH, Zhang H, et al · · 2022 · cited 591× · PMID 35794095 · DOI 10.1038/s41392-022-01064-1
The Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke.
Wicks EE, Ran KR, Kim JE, Xu R, et al · · 2022 · cited 68× · PMID 35795678 · DOI 10.3389/fimmu.2022.897022
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.
Pournajaf S, Dargahi L, Javan M, Pourgholami MH. · · 2022 · cited 40× · PMID 35250559 · DOI 10.3389/fphar.2022.807639
Thinking outside the Ischemia Box: Advancements in the Use of Multiple Sclerosis Drugs in Ischemic Stroke.
Aloizou AM, Siokas V, Pateraki G, Liampas I, et al · · 2021 · cited 23× · PMID 33562264 · DOI 10.3390/jcm10040630
Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage.
Khan SA, Goliwas KF, Deshane JS. · · 2021 · cited 17× · PMID 34690821 · DOI 10.3389/fphys.2021.760638
Adjunctive cytoprotective therapies in acute ischemic stroke: a systematic review.
Mulder IA, van Bavel ET, de Vries HE, Coutinho JM. · · 2021 · cited 15× · PMID 34666786 · DOI 10.1186/s12987-021-00280-1
Sphingosine-1-Phosphate Signaling in Ischemic Stroke: From Bench to Bedside and Beyond.
Zhang SQ, Xiao J, Chen M, Zhou LQ, et al · · 2021 · cited 12× · PMID 34916911 · DOI 10.3389/fncel.2021.781098
Barrier maintenance by S1P during inflammation and sepsis.
Ziegler AC, Gräler MH. · · 2021 · cited 10× · PMID 34152926 · DOI 10.1080/21688370.2021.1940069

Verify or expand the search:

Other trials of Fingolimod

Trials testing the same drug.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT07220252 — Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis · Phase 2, PHASE3 · not yet recruiting
NCT06408259 — Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relap · Phase 3 · recruiting
NCT06087965 — Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage · Phase 1, PHASE2 · unknown
NCT05123703 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Re · Phase 3 · active not recruiting

Other Ning Wang, MD., PhD. trials

Trials by the same sponsor.

NCT04637074 — A Cohort Study on Thrombectomy for Stroke · unknown
NCT04386018 — A Registered Cohort Study of Inflammatory Demyelination Disease · unknown
NCT04303962 — Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome · unknown
NCT04010188 — A Registered Cohort Study on Charcot-Marie-Tooth Disease · recruiting
NCT04012671 — A Registered Cohort Study on Duchenne Muscular Dystrophy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04629872 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ning Wang, MD., PhD.
Last refreshed: 13 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04629872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing